Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and…
USD29.06+6.41%vs prev. close
Performance
1W
-29.61%
1M
-35.56%
3M
-51.12%
1Y
-62.42%
YTD
-65.48%
Valuation
P/E
—
EPS TTM
-3.35
Dividend yield
—
Size and risk
Market cap
$4.5B
Beta
0.40
Price history
IONS price
USD
Total returnEventsVs index
Loading…
Next earnings
Report date
EPS estimate
Revenue estimate
Peer comparison
Ionis Pharmaceuticals
IONS
Biotechnology
Mkt cap (USD bn)
4.5
P/E
—
Div yld
—
1W
-29.6%
1M
-35.6%
3M
-51.1%
6M
-63.9%
1Y
-62.4%
YTD
-65.5%
Company
Ticker
Industry
Mkt cap (USD bn)
P/E
Div yld
1W
1M
3M
6M
1Y
YTD
Ionis Pharmaceuticals
IONS
Biotechnology
4.5
—
—
-29.6%
-35.6%
-51.1%
-63.9%
-62.4%
-65.5%
Subscribe to Equity Analytics to compare IONS with its closest peers
Sector-matched peer set with side-by-side valuation, dividend and performance over every window.